With more than 30 years of television experience, Gary has established himself as a leader in the industry when it comes to assisting viewers and resolving consumer-related issues. His passion and ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Gary Mason began his journalism career in British Columbia in 1981, working as a summer intern for Canadian Press. One of his first assignments was covering the last days of the province's ...